Clinical Evidence
ANTIMICROBIAL EFFICACY DEMOSTRATED IN VIVO AND IN VITRO
19th International Conference on Wound Management 25th -26th May, 2017 – London (UK)
R. Cassino, V. Dissette, C.A. Bignozzi, D. Pazzi
Study objective
Comparison between SCX technology (silver-based spray) and Silver Sulfadiazine (SSD) in the management of infectious wounds.
Methodology
- Patients with infectious wounds
- Comparative evaluation: SCX spray vs SSD
- Monitoring infection signs and wound evolution
Key findings
- SCX demonstrated superior efficacy compared to SSD
- Faster reduction of infection signs
- Improved wound healing environment
- Better local tolerance
Clinical relevance
- Modern alternative to traditional SSD therapy
- Supports local infection control
- Optimizes wound healing conditions
- Suitable for routine clinical use
In Vitro
In vitro efficacy tests of SCX versus SSD performed on a pool of 5 strains: Pseudomonas Aeruginosa, Staphylococcus aureus, Escherichia Colocus hirae and Candida Albicans.
Results after incubation in Petri dishes at 37° C of 100 μl of the pool with SCX and SSD:
SCX - 5 days after
SCX has demonstrated a large ring of inhibition lasting for more than 5 days.
SSD - 5 days after
SSD has demonstrated a good ring of ihibition that lasted 24 hours, but after 5 days there were no longer signs of inhibition
In Vivo
Evaluation performed on 10 chronic infected lesions treated with SSD powder spray every 48 hours for 14 days and, after worsening, treated with SCX powder spray every 48 hours for 14 days.
Complete disappearance of clinical signs of infection.
Disappearance of erythema at the edges of the lesion. Perfect results correspondance between antimicrobial action in vitro and in vivo.
Beginning of the study
After 14 days of treatment with silver sulfadiazine (SSD)
After 14 days of treatment with SiO2 Ag+ Chlorhexidine (SCX powder spray)
Conclusion
| SilverSulfaDiazine Treatment | |||||
|---|---|---|---|---|---|
| Infection Signs* | W. E. Erythema** | ||||
| T0 | T7 | T14 | T0 | T7 | T14 |
| 2.2 | 2.7 +22.7% |
3.8 +72.7% |
1 10% |
5 50% |
10 100% |
| SiO2-Ag+Chlorex Treatment | |||||
|---|---|---|---|---|---|
| Infection Signs* | W. E. Erythema** | ||||
| T0 | T7 | T14 | T0 | T7 | T14 |
| 3.8 | 1.6 -57.9% |
0.3 -92.1% |
10 100% |
2 20% |
— |
CLINICAL EVIDENCE – DIABETIC FOOT
L’uso dell ‘ argento ionico nella cura del piede diabetici : preventione e trattamento dell’ infectione
Roberto Cassino, AnnaMaria Ippolito
Indication
Mechanism
- Broad antimicrobial effect
- Reduces bacterial load
- Controls exudate
Clinical benefits
- Reduced infection signs
- Improved tissue condition
- Supports granulation
Outcome
- Faster lesion evolution
- Improved healing conditions
- Good tolerability
Before treatment
Diabetic foot ulcer – infected lesion
After 14 days of KAdermin Spray application
Clinical signs of infection disappeared and lesion size was significantly reduced
TRIPLE ACTION ON CHRONIC LESIONS
6th Congress of WORLD UNION of WOUND HEALING SOCIETIES – Abu Dhabi, UAE
R. Cassino RSA “Sacra Famiglia“ Pieve del Cairo (PV)
Group 1: Colonized wounds with slough (WBP score C)
Slough removal
within 12 days
Group 2: Infected wounds
Disappearance of infection signs
within 2 weeks
Group 3: Sacralbedsores
CLINICAL EXPERIENCE IN PEDIATRIC PATIENTS
Department of Paediatric Surgery, Department of Paediatric Surgery and Intensive Care, Division of Surgery, University Medical Centre Ljubljana
Marjanca Kovše, MNSc, Sabina Kaplan, registered nurse
At the Department of Pediatric Surgery, we monitored three children with inflamed and macerated skin. We used KAdermin antimicrobial spray, which was applied to the clean and washed skin surface several times a day.
The spray proved to be good for treating macerated skin and fungal rash, as the skin breathes under the sprayed layer. The improvement was rapid.
FIRST CASE
The first child is a premature infant (33 weeks) who was operated on at birth due to the transposition of the great arteries, and later due to hydrocephalus. She was fed via a nasogastric tube, and spoon-feeding was gradually introduced at the age of 6 months. The increased defecation resulted in gluteal redness that occurred on 1 October 2018.
Before treatment
After 10 days of KAdermin Spray application
Visible reduction of erythema and skin irritation, with progressive skin recovery
SECOND CASE
Descendostomy and mucous fistula were performed due to atresia of the anus. Both stomas and the area between the stomas were covered by pads soaked in a physiological solution. Although the pads were changed regularly, fungal infection of the skin occurred on 9 February 2019 and resulted in a wound. We decided to use the antimicrobial spray along the bandage. On 18 February, the wound was healed and
we were able to place the stoma bag.
Before treatment
After 9 days of KAdermin Spray application
Reduction of inflammatory signs and progressive healing of the affected skin area
Randomized Blind Study EPUAP Meeting, Ghent (Belgium), 2015
18th Annual European Pressure Ulcer Advisory Panel Meeting
16th – 18th September, 2015 – Ghent, Belgium
ANTISEPTIC DRESSINGS: A COMPARISON IN A RANDOMIZED BLIND STUDY
Study Design
• 15 patients with infected pressure ulcers
• 3-week treatment period
• Comparison between:
– Povidone-Iodine Gauze
– Activated Charcoal + Silver Dressing
– SiO₂ + Ag⁺ + Chlorhexidine (SCX Technology)
Key Results
Activated Charcoal + Silver: 6.0 → 0.6 infection signs
Povidone-Iodine Gauze: 5.4 → 3.8 infection signs
SCX Technology (KAdermin): 6.0 → 0.0 infection signs
Key Takeaway
✓ Complete resolution of infection signs after 3 weeks.
SCX Technology demonstrated superior infection control compared with povidone-iodine gauze and performed at least as effectively as silver dressings.
| SIGNS OF INFECTION | ||
|---|---|---|
| Products | Beginning of the study | End of study (3 weeks) |
| Activated Charcoal & Silver | 6.0 | 0.6 |
| Povidoiodine Gauze | 5.4 | 3.8 |
| SiO2– Ag+ Chlorex | 6.0 | — |
| AREA REDUCTION (or VARIATION) | |
|---|---|
| Products | End of study (3 weeks) |
| Activated Charcoal & Silver | – 3.5% |
| Povidoiodine Gauze | + 7.4% |
| SiO2– Ag+ Chlorex | – 25.6% |
Clinical Evidence in Venous Leg Ulcers
Clinical Evidence in Venous Leg Ulcers (VLU) EWMA Congress,
Bremen (Germany), 2016
SCX Technology demonstrated clinical efficacy in venous leg ulcer management and enhanced healing outcomes when combined with standard therapy.
Study Design
• 40 patients with venous leg ulcers (<6 months duration)
• 8-week treatment period
• 4 treatment groups (10 patients/group)
Group 1: Compression therapy
Group 2: Compression + Diosmin
Group 3: Compression + SCX Technology
Group 4: Compression + Diosmin + SCX Technology
Objective
To evaluate the synergistic effect of pure synthetic diosmin and SCX Technology (SiO₂ + Ag⁺ + Chlorhexidine).
Key Finding
All treatment groups achieved wound area reduction, with the greatest improvement observed when diosmin and SCX Technology were used together.
| MEAN AREA REDUCTION | |||
|---|---|---|---|
| Group 1 | Group 2 | Group 3 | Group 4 |
| 62.7% | 71.6% | 72.5% | 78,6% |
| Control | + 14.2% | + 15.7% | + 25.4% |
